Cat. No.: HY-120934

C25-140

28 Cited Publications

Customer Review

Based on 28 publication(s) in Google Scholar

C25-140, a first-in-class, orally active, and fairly selective TRAF6-Ubc13 inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces NF-κB activation, and combats autoimmunity.

For research use only. We do not sell to patients.

Purity: 99.92%
CAS No.: 1358099-18-9
Formula: C₂₆H₃₁N₇O
Molecular Weight:457.57

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

C25-140 Chemical Structure

CAS No.: 1358099-18-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (28)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

TRAF6-Ubc13^[1]

All TNF Receptor Isoforms :

In Vitro

C25-140 dose-dependently impedes TRAF6-Ubc13 interaction^[1].
C25-140 (10-30 μM; 2 hours) effectively reduces TRAF6-mediated ubiquitin chain formation^[1].
C25-140 affects TNFα-induced phosphorylation of IκBα as well as NF-κB-induced target gene expression^[1].
C25-140 efficiently inhibits IL-1β- and TNFα-mediated receptor signaling in the context of cytokine activation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

TRAF6_WT
Concentration:

10 μM, 20 μM, 30 μM
Incubation Time:

2 hours
Result:

Effectively reduced TRAF6-mediated ubiquitin chain formation.

In Vivo

C25-140 (~1.5 mg/kg; topically to the shaved back and the right ear; twice daily for 6 days) ameliorates symptoms of autoimmune psoriasis in R 837-induced psoriasis mouse model^[1].
C25-140 (6-14 mg/kg; given i.p.; twice daily for 14 days) shows a dose-dependent improvement of RA disease outcome in Collagen-induced arthritis (CIA) model^[1].
C25-140 (10 mg/kg; i.v.) treatment shows that the C_max, AUC, t_1/2 and V_d are 9.7 μg/mL, 274083 ng min/mL, 80.62 min, and 4.13 L/kg, respectively^[1].
C25-140 (10 mg/kg; p.o.) treatment shows that the C_max, AUC, t_1/2 and V_d are 3.4 μg/mL, 124034 ng min/mL, 127.33 min and 13.3 L/kg, respectively^[1].
C25-140 (10 mg/kg; i.p.) treatment shows that the C_max, AUC, t_1/2 and V_d are 4.2μg/mL, 100000 ng min/mL, 184 min, 25.6 L/kg, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

R 837-induced psoriasis mouse model (male BALB/c mice)^[1]
Dosage:

~1.5 mg/kg
Administration:

Topically to the shaved back and the right ear; twice daily for 6 days
Result:

Showed a dose-dependent improvement of RA disease outcome.

Animal Model:

Collagen-induced arthritis (CIA) model in DBA1/J mice^[1]
Dosage:

6 mg/kg, 10 mg/kg, 14 mg/kg
Administration:

Given i.p.; twice daily for 14 days
Result:

Ameliorated the arthritic index to almost baseline levels in this efficacy model at doses of 10 and 14 mg/kg. Dose-dependently improved symptoms of RA including inflammation and structural damage.

Animal Model:

BALB/C mice^[1]
Dosage:

10 mg/kg
Administration:

I.v. (Pharmacokinetic Analysis)
Result:

The C_max, AUC, t_1/2 and V_d were 9.7 μg/mL, 274083 ng min/mL, 80.62 min, and 4.13 L/kg, respectively.

Chemical Information

CAS No. 1358099-18-9
Appearance Solid
Molecular Weight 457.57
Formula C₂₆H₃₁N₇O
Color White to off-white
SMILES

O=C(N1CCC(CC2=CC=CC=C2)CC1)CCC3=C(C)N(C4=NN5C(C=C4)=NN=C5C)N=C3C
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (28)

All In Vivo Efficacy StudyWBBio/Physico-chemical AssayFlow Cytometry

Sort by:

Journal Impact Factor

Bone Res

SMN deficiency inhibits endochondral ossification via promoting TRAF6-induced ubiquitination degradation of YBX1 in spinal muscular atrophy. [Abstract]

2025 Dec 1;13(1):97. PMID: 41320719

C25-140 purchased from MedChemExpress. Usage Cited in: Bone Res. 2025 Dec 1;13(1):97. [Abstract]

Western blotting analyses of the effect of C25-140 (20 mol/L, 0-10 h) on YBX1 stability in ATDC5 cells at the indicated time points. GAPDH was used as the loading control.
Nat Commun

APIP regulates the priming of canonical NLRP3 and non-canonical Caspase-11/4 inflammasomes by binding to TRAF6. [Abstract]

2025 Dec 3;16(1):10866. PMID: 41339302

C25-140 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Dec 3;16(1):10866. [Abstract]

WT and APIP^TG/+ mice (10–12 weeks) were injected with LPS (15 mg/kg, 8 h) alone or with C25-140 (14 mg/kg, three doses at 12 h intervals, last dose 4 h before LPS).
Theranostics

Sufu limits sepsis-induced lung inflammation via regulating phase separation of TRAF6. [Abstract]

2023 Jun 26;13(11):3761-3780. PMID: 37441604
Sci Adv

TRAF6 integrates innate immune signals to regulate glucose homeostasis via Parkin-dependent and Parkin-independent mitophagy. [Abstract]

2025 Oct 10;11(41):eadw4153. PMID: 41061082

C25-140 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Oct 10;11(41):eadw4153. [Abstract]

GSIS in human islets treated with DMSO or 1 μM C25-140 for 24 hours and exposed to glucolipotoxicity (GLT; 25 mM glucose + 0.5 mM palmitate) or control (5 mM glucose + BSA) for 48 hours. n = 4 to 5 per group.

C25-140 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Oct 10;11(41):eadw4153. [Abstract]

Insulin content in human islets treated with DMSO or 1 μM C25-140 for 24 hours and exposed to GLT or control for 48 hours. n = 4 to 5 per group.

C25-140 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Oct 10;11(41):eadw4153. [Abstract]

Flow cytometry quantification of mitophagy flux in β cells from mt-Keima mice fed 15-week RFD or HFD, exposed to DMSO or 1 μM C25-140 for 24 hours. n = 3 per group.

C25-140 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Oct 10;11(41):eadw4153. [Abstract]

Flow cytometry quantification of mitophagy flux in human β cells exposed to DMSO or 1 μM C25-140 for 24 hours and exposed to GLT or control for 48 hours.
J Neuroinflammation

The YTHDF1-TRAF6 pathway regulates the neuroinflammatory response and contributes to morphine tolerance and hyperalgesia in the periaqueductal gray. [Abstract]

2022 Dec 22;19(1):310. PMID: 36550542
Phytomedicine

The anti-inflammatory activity by suppressing the TRAF6/MAPKs pathway of trishizukaol a from Sarcandra glabra. [Abstract]

2022 Apr:98:153952. PMID: 35121389
Free Radic Biol Med

Fyn deficiency drives pro-inflammatory macrophage activation to exacerbate septic acute lung injury. [Abstract]

2026 Mar 16:246:80-92. PMID: 41490764
Clin Nutr

2'-Fucosyllactose restores the intestinal mucosal barrier in ulcerative colitis by inhibiting STAT3 palmitoylation and phosphorylation. [Abstract]

2024 Feb;43(2):380-394. PMID: 38150914
Int Immunopharmacol

miR-194 ameliorates hepatic ischemia/reperfusion injury via targeting PHLDA1 in a TRAF6-dependent manner. [Abstract]

2021 Jul:96:107604. PMID: 33839577
Int Immunopharmacol

TLR4/TRAF6/NOX2 signaling pathway is involved in ventilation-induced lung injury via endoplasmic reticulum stress in murine model. [Abstract]

2021 Jul:96:107774. PMID: 34020396
Mol Neurobiol

Transmission of NLRP3-IL-1β Signals in Cerebral Ischemia and Reperfusion Injury: from Microglia to Adjacent Neuron and Endothelial Cells via IL-1β/IL-1R1/TRAF6. [Abstract]

2023 May;60(5):2749-2766. PMID: 36717480
Front Pharmacol

Dehydrocorydaline Protects Against Sepsis-Induced Myocardial Injury Through Modulating the TRAF6/NF-κB Pathway. [Abstract]

2021 Aug 19:12:709604. PMID: 34489703
Int Dent J

Pulpal Pressure Aggravates Pulpitis by Mechano-Inflammatory Signal Synergy. [Abstract]

2026 Jun 27;76(5):109698. PMID: 42364415
Cancers (Basel)

TRAF6 Promotes PRMT5 Activity in a Ubiquitination-Dependent Manner. [Abstract]

2023 Apr 27;15(9):2501. PMID: 37173967
Neuropharmacology

TIM3 attenuates morphine antinociceptive tolerance and microglial neuroinflammation by suppressing the TRAF6/NF-κB pathway in male mice. [Abstract]

2025 Nov 15:279:110638. PMID: 40840715
ACS Chem Neurosci

ULK1 Knockout Exacerbates Ischemia-Induced Microglial Dysfunction via TRAF6/NF-κB Signaling Pathway. [Abstract]

2025 Aug 6;16(15):2978-2988. PMID: 40708226
FASEB J

Fish NF-κB couples TCR and IL-17 signals to regulate ancestral T-cell immune response against bacterial infection. [Abstract]

2021 Apr;35(4):e21457. PMID: 33689192
J Virol

Highly pathogenic porcine reproductive and respiratory syndrome virus nonstructural protein 1 interacts with TRAF6 to activate the TAK1/p38/JNK/AP-1 signaling and induce IL-1β. [Abstract]

2026 Jun 12:e0042826. PMID: 42283627
Virol J

Interleukin-17A pretreatment attenuates the anti-hepatitis B virus efficacy of interferon-alpha by reducing activation of the interferon-stimulated gene factor 3 transcriptional complex in hepatitis B virus-expressing HepG2 cells. [Abstract]

2022 Feb 10;19(1):28. PMID: 35144643
Mol Pain

TLR3 mediates central sensitization in a chronic migraine model induced by repeated nitroglycerin through the ERK signaling pathway. [Abstract]

2025 Jan-Dec:21:17448069251346373. PMID: 40407181
Parasit Vectors

Toxoplasma gondii-induced adverse pregnancy outcomes: insight into the inhibitory role of Trem2 on TLR4/TRAF6/JNK signaling pathway. [Abstract]

2025 Oct 6;18(1):396. PMID: 41053868
Mol Immunol

FAM49B, restrained by miR-22, relieved hepatic ischemia/reperfusion injury by inhibiting TRAF6/IKK signaling pathway in a Rac1-dependent manner. [Abstract]

2022 Mar:143:135-146. PMID: 35131594
PLoS One

A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]

2024 Nov 1;19(11):e0308647. PMID: 39485774
University of Michigan

2025.
SSRN

2025 Apr 30.
bioRxiv

TRAF6 integrates innate immune signals to regulate glucose homeostasis via Parkin-dependent and -independent mitophagy. [Abstract]

2025 Feb 1:2025.01.31.635900. PMID: 39974969
Heliyon

SARS-CoV-2 activates the TLR4/MyD88 pathway in human macrophages: A possible correlation with strong pro-inflammatory responses in severe COVID-19. [Abstract]

2023 Nov 17;9(11):e21893. PMID: 38034686
Research Square Print

2022 Aug.

Solvent & Solubility

In Vitro:

DMSO : 41.67 mg/mL (91.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1855 mL

10.9273 mL

21.8546 mL

5 mM

0.4371 mL

2.1855 mL

4.3709 mL

10 mM

0.2185 mL

1.0927 mL

2.1855 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Brenke JK, et al. Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity. J Biol Chem. 2018 Aug 24;293(34):13191-13203. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1855 mL	10.9273 mL	21.8546 mL	54.6364 mL
	5 mM	0.4371 mL	2.1855 mL	4.3709 mL	10.9273 mL
	10 mM	0.2185 mL	1.0927 mL	2.1855 mL	5.4636 mL
	15 mM	0.1457 mL	0.7285 mL	1.4570 mL	3.6424 mL
	20 mM	0.1093 mL	0.5464 mL	1.0927 mL	2.7318 mL
	25 mM	0.0874 mL	0.4371 mL	0.8742 mL	2.1855 mL
	30 mM	0.0728 mL	0.3642 mL	0.7285 mL	1.8212 mL
	40 mM	0.0546 mL	0.2732 mL	0.5464 mL	1.3659 mL
	50 mM	0.0437 mL	0.2185 mL	0.4371 mL	1.0927 mL
	60 mM	0.0364 mL	0.1821 mL	0.3642 mL	0.9106 mL
	80 mM	0.0273 mL	0.1366 mL	0.2732 mL	0.6830 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

C25-140

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Ubiquitination Compound Library

Pyroptosis Compound Library

Angiogenesis-Related Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Amino Acid Metabolism Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Anti-Cancer Compound Library

Publications Citing Use of MedChemExpress (MCE) C25-140

All TNF Receptor Isoforms

Biological Activity

Chemical Information

Publications (28)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

C25-140 Related Classifications

HY-120934 Related Classifications